Skip to content

Comparing neonatal outcome following use of ondansetron and pyridoxine in pregnant women with morning sickness

Comparing neonatal outcome following use of ondansetron and pyridoxine in pregnant women with morning sickness who referred to community health centers in Zabol in 2014

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015082523749N1
Enrollment
150
Registered
2015-09-15
Start date
2014-06-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Excessive vomiting in pregnancy. Excessive vomiting in pregnancy

Interventions

Intervention 1: Intervention group was included 88 primipara singleton pregnant women suffered from moderate degree of morning sickness, received 4 mg Ondansetron every 12 hours until improving the s
Treatment - Drugs
Intervention group was included 88 primipara singleton pregnant women suffered from moderate degree of morning sickness, received 4 mg Ondansetron every 12 hours until improving the symptoms (vomitti
Control group was consisted of 100 primipara singleton pregnant women suffered from moderate degree of morning sickness, received 40 mg Pyridoxine every 12 hours until improving the symptoms (vomittin

Sponsors

Zabol University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
14 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: primipara singleton pregnant women with pregnancy-related nausea and vomiting who referred to community health centers in Zabol in 2014. Exclusion criteria: multi-gestational status; refusing the patients for study medications; history of sensitivity to drugs; other underlying disorders such as migraine headache, acute gastroenteritis, acute appendicitis, hepatitis, mole hydatiform, or urinary tract infections; using other types of antiemetic drugs with the recent weeks; drug dependence or the use of contraceptives.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Anthropometric parameters. Timepoint: At birth. Method of measurement: Height and head circumference in cm with Meter and weight in Kg with balance.

Secondary

MeasureTime frame
Neonatal Anomaly. Timepoint: At birth. Method of measurement: by history and physical examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Shahraki

Zabol university of medical sciences

zshahraki@razi.tums.ac.ir+98 54 3229 5117

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026